Ro 08-2750
CAS No. : 37854-59-4
| Size | Price | Stock |
|---|---|---|
| 5mg | $75 | In-stock |
| 10mg | $120 | In-stock |
| 25mg | $240 | In-stock |
| 50mg | $380 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-108466 |
| M.Wt: | 270.24 |
| Formula: | C13H10N4O3 |
| Purity: | >98 % |
| Solubility: | DMSO : 4 mg/mL (ultrasonic;warming;heat to 80°C) |
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 µM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA[1]. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM[3].
IC50 & Target:IC50: ~1 µM (NGF)[1], 2.7 μM (MSI RNA-binding)[3]
In Vitro:Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore[2].
Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death[2].
Ro 08-2750 (5-10 μM; 8 hours) increases differentiation and apoptosis in myeloid leukemia cells[3].
Ro 08-2750 inhibits survival of human AML lines and patient cells[3].
Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature[3].
In Vivo:Ro 08-2750 (13.75 mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Ro 08-2750
- Cat. No.:
- HY-108466
- Quantity:
Your information is safe with us.